PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-15.30%
Both companies show declining cash positions (-15.30% vs TRAW's -47.05%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-15.30%
Below half of TRAW's -47.05%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.91%
Below half of TRAW's -43.69%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-12.74%
0.5-0.75x TRAW's -22.89%. Martin Whitman might see a risk of falling behind in asset investment or shifting strategy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.02%
Higher Other Non-Current Assets Growth compared to TRAW's zero value, indicating worse performance.
-1.64%
Below half of TRAW's -20.00%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-15.58%
Below half of TRAW's -43.43%. Michael Burry sees a potential red flag for stagnation or capital shortage.
72.22%
Above 1.5x TRAW's 13.80%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-79.94%
Less than half of TRAW's 33.12%. David Dodd sees fewer expansions in other current obligations.
32.21%
Above 1.5x TRAW's 10.98%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.21%
Above 1.5x TRAW's 6.45%. Michael Burry sees a potential leverage warning sign.
0.06%
Less than half of TRAW's -91.92%. David Dodd sees fewer share issuances vs. competitor.
-3.27%
≥ 1.5x TRAW's -1.74%. David Dodd sees higher yoy retained profits than competitor.
0.51%
Less than half of TRAW's 400.00%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-24.85%
Below half TRAW's -69.24%. Michael Burry sees potential underperformance in building shareholder capital.
-15.58%
Below half TRAW's -43.43%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
15.30%
Less than half of TRAW's 47.05%. David Dodd sees better deleveraging or stronger cash buildup than competitor.